Condition (MeSH)
Hyperlipoproteinemia Type III
ClinicalTrials.gov lists 10 trials for Hyperlipoproteinemia Type III or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
10 of the 10 trials are tagged with Hyperlipoproteinemia Type III itself; the rest are tagged with a narrower condition beneath it.
When did Hyperlipoproteinemia Type III trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2022 | 1 |
| 2020 | 1 |
| 2019 | 1 |
| 2017 | 1 |
| 2013 | 1 |
| 2005 | 2 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hyperlipoproteinemia Type III trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 3 | 2 |
| Phase 4 | 1 |
| Not applicable | 3 |
| Observational | 3 |
| Expanded access | 1 |
How many Hyperlipoproteinemia Type III trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Active, not recruiting | 1 |
| Completed | 3 |
| Approved for marketing | 1 |
| Terminated | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hyperlipoproteinemia Type III trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Abu Dhabi Health Services Company | 1 |
| AstraZeneca | 1 |
| National Heart, Lung, and Blood Institute (NHLBI) | 1 |
| National Medical Research Center for Therapy and Preventive Medicine | 1 |
| Pfizer | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Hyperlipoproteinemia Type III? (3)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| ROSUVASTATIN | 1 |
| ATORVASTATIN | 1 |
| Evinacumab | 1 |
Interventions as named in the registry (4)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Pravastatin Pill | 1 |
| Fenofibrate IDD-P (Insoluble Drug Delivery-Micro Particle) | 1 |
| Evolocumab Auto-Injector [Repatha] | 1 |
| Torcetrapib/Atorvastatin | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Hyperlipoproteinemia Type III? (9)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial. | Journal of the American Heart Association | 2025 | Yes |
| Importance of the triglyceride level in identifying patients with a Type III Hyperlipoproteinemia phenotype using the ApoB algorithm. | Journal of clinical lipidology | 2021 | Yes |
| Case series of type III hyperlipoproteinemia in children. | BMJ case reports | 2011 | Yes |
| Screening for dysbetalipoproteinemia by plasma cholesterol and apolipoprotein B concentrations. | Clinical chemistry | 2005 | Yes |
| Familial apolipoprotein E deficiency. | The Journal of clinical investigation | 1986 | Yes |
Showing 5 of 9 publications.
Prevalence (4)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Dysbetalipoproteinemia | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| Dysbetalipoproteinemia | Point prevalence | 1-9 / 100 000 | Europe | Not stated | Exact |
| Dysbetalipoproteinemia | Point prevalence | 1-5 / 10 000 | Worldwide | Not stated | Exact |
| Dysbetalipoproteinemia | Point prevalence | 1-5 / 10 000 | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Dysbetalipoproteinemia | 412 | Exact | Orphadata Science knowledge files, Product 1 |
| Dysbetalipoproteinemia | 412 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.